APA (7th ed.) Citation

Ko, D., Park, S., Park, M., Kim, S., Park, J. M., Seo, J., . . . Seo, J. H. (2025). Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer. Experimental Hematology & Oncology, 14(1), 1. https://doi.org/10.1186/s40164-025-00716-6

Chicago Style (17th ed.) Citation

Ko, Dongmi, et al. "Pitavastatin Is a Novel Mcl-1 Inhibitor That Overcomes Paclitaxel Resistance in Triple-negative Breast Cancer." Experimental Hematology & Oncology 14, no. 1 (2025): 1. https://doi.org/10.1186/s40164-025-00716-6.

MLA (9th ed.) Citation

Ko, Dongmi, et al. "Pitavastatin Is a Novel Mcl-1 Inhibitor That Overcomes Paclitaxel Resistance in Triple-negative Breast Cancer." Experimental Hematology & Oncology, vol. 14, no. 1, 2025, p. 1, https://doi.org/10.1186/s40164-025-00716-6.